Fig. 4From: Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomyOverall survival in the NT+S and NT−S cohorts, divided per histology (AC and SCC). NT+S neoadjuvant treatment plus surgery, NT−S neoadjuvant treatment without surgery, AC adenocarcinoma, SCC squamous cell carcinomaBack to article page